NervGen Pharma (TSXV:NGEN) COGS-to-Revenue : 0.00 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma COGS-to-Revenue?

NervGen Pharma's Cost of Goods Sold for the three months ended in Sep. 2024 was C$0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was C$0.00 Mil.

NervGen Pharma's COGS to Revenue for the three months ended in Sep. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NervGen Pharma's Gross Margin % for the three months ended in Sep. 2024 was N/A%.

NervGen Pharma COGS-to-Revenue Historical Data

The historical data trend for NervGen Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma COGS-to-Revenue Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

NervGen Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

NervGen Pharma COGS-to-Revenue Calculation

NervGen Pharma's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

NervGen Pharma's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

NervGen Pharma (TSXV:NGEN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NervGen Pharma's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NervGen Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

NGENF:USA 9UA:Germany

Address

112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4

Website

https://www.nervgen.com

NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.

Executives

John Ruffolo	Director
Krista Mckerracher	Director
William Joseph Radvak	Director
Harold Punnett	10% Security Holder, Director
Robert Pilz	Senior Officer

NervGen Pharma Headlines

No Headlines